Adult Dosing
Niacin deficiency
Treatment
- Upto 500 mg PO in divided doses
Prophylaxis
Hyperlipidemias
Immediate release TABS
- Initial: 100500 mg/day PO; increase slowly up to 12 g/day PO tid. Max: 8 g/day PO
Extended release TABS
- Monotherapy:
- 500-2000 mg PO Daily
- Initial: 500 mg PO qhs; increase dose by not more than 500 mg in any 4 wks period
- Maintenance: 1000-2000 mg/day PO x1. Max: 2000 mg/day PO
- Combination therapy with lovastatin:
- Initial: lovastatin 20 mg/day PO. Max: 40 mg/day PO
- Max: niacin 2000 mg/day PO
- Combination therapy with simvastatin:
- Initial: simvastatin 20 mg/day PO. Max: 40 mg/day PO
- Max: niacin 2000 mg/day PO
Pediatric Dosing
Niacin deficiency prophylaxis
- Child birth-3yrs: 5-9 mg/day PO
- Child 4-6 yrs: 12 mg/day PO
- Child 7-10 yrs: 13 mg/day PO
Note:
- Safety and effectiveness of niacin therapy (Extended Release TABS) in pediatric patients (+<16 years) have not been established
[Outline]
- Events of severe hepatic toxicity, including fulminant hepatic necrosis have been reported in patients who have substituted sustained-release therapy for immediate-release therapy. Therefore periodically perform liver function tests during the therapy
- Concomitant use of lipid-altering doses (1 g/day) of niacin and HMG-CoA reductase inhibitors may cause rhabdomyolysis. Weigh the potential benefits and risks before instituting such therapy and carefully monitor patients for any signs and symptoms of muscle pain, tenderness, or weakness
- Prior to initiating therapy make an attempt to control hyperlipidemia with appropriate diet, exercise, and weight reduction in obese patients, and to treat other underlying medical problems
- Cautiously administer therapy in patients with history of jaundice, hepatobiliary disease, or peptic ulcer. Liver function tests and blood glucose should be frequently performed
- Closely monitor and adjust dosage/diet accordingly as diabetic patients may experience a dose-related rise in glucose intolerance
- Caution advised in patients with unstable angina or in the acute phase of myocardial infarction
- Use with caution in patients predisposed to gout because elevated uric acid levels have occurred with the therapy
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- History of biliary disease
- History of PUD
- Alcohol abuse
- Diabetes mellitus
- Gout
- Unstable angina
- Acute MI
- Hypophosphatemia
- Surgery
Pregnancy Category:C
Breastfeeding: Safety unknown. Due to the potential for serious adverse reactions in nursing infants, manufacturer recommends discontinuation of nursing or discontinuation of drug, taking into account the importance of the drug to the mother.
Pricing data from www.DrugStore.com in U.S.A.
- Niaspan 500 MG TBCR [Bottle] (ABBOTT)
30 mg = $89.99
90 mg = $246.97 - Niaspan 1000 MG TBCR [Bottle] (ABBOTT)
30 mg = $161.98
90 mg = $466.97 - Niacin 500 MG TABS [Bottle] (RUGBY)
100 mg = $11.99
200 mg = $16.96 - Niaspan 750 MG TBCR [Bottle] (ABBOTT)
30 mg = $124.99
90 mg = $347.95
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.